Viral load suppression and acquired HIV drug resistance in adults receiving antiretroviral therapy in Viet Nam: results from a nationally representative survey
DOI:
https://doi.org/10.5365/wpsar.v9i3.596Abstract
Objective: Purpose of this survey was to estimate prevalence of viral load (VL) suppression and emergence of HIV drug resistance (HIVDR) among individuals receiving antiretroviral therapy (ART) for 36 months or longer in Vietnam using a nationally representative sampling method.
Methods: The survey was conducted between May and August 2014, using a two-stage cluster design. Sixteen ART clinics were selected using probability proportional to proxy size sampling, and patients receiving ART for at least 36 months were consecutively enrolled. Epidemiological information and blood specimens were collected for HIV-1 VL and HIVDR testing HIVDR was defined by the Stanford HIV drug resistance algorithm.
Results: Overall, 365 eligible individuals were recruited with mean age of 38.2. 68.4% were males and the mean time on ART was 75.5 months (95%CI 69.0-81.9). 93.7% of the patients were receiving non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. Of the 365 individuals, 345 (94.7%, 95% CI 64.1-99.4%) had VL below 1,000 copies/mL and 19 (4.6%, 95%CI 2.8-7.5) had HIVDR mutations.
Discussion: Present survey was one of the first to describe viral load suppression and ADR using nationally representative sample following new WHO guidance. The results suggest high prevalence of VL suppression and low prevalence of ADR among individuals who receive ART for at least 36 months in Vietnam.
References
The Joint United Nations Programme on HIV/AIDS (UNAIDS) Vietnam. Know your epidemic 2017 [Available from: http://unaids.org.vn/en/know-your-epidemic/.
VAAC. Global AIDS Monitoring 2017 - Report from Vietnam. Hanoi, Vietnam: Viet Nam Authority of HIV/AIDS Control; 2017.
Vietnam Ministry of Health. Reporting on HIV/AIDS prevention in 2015 and important mission in 2016. 2016.
Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008;13 Suppl 2:15-23.
WHO. Surveillance of HIV drug resistance in adults receiving ART (acquired HIV drug resistance). Geneva, Switzerland: World Health Organization; 2014.
World Health Organization. Surveillance of HIV drug resistance in adults receiving ART (acquired HIV drug resistance). Geneva, Switzerland: WHO Document Production Services; 2014.
HIVdb Program: Genotypic Resistance Interpretation Algorithm [Internet]. [cited 15th May 2015]. Available from: http://hivdb.stanford.edu/index.html.
World Health Organization USCfDCaP, The Global Fund to Fight AIDS, Tuberculosis and Malaria. HIV drug resistance report 2017. Geneva, Switzerland: World Health Organization; 2017. Available from: http://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/.
Nguyen HT, Duc NB, Shrivastava R, Tran TH, Nguyen TA, Thang PH, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther. 2008;13 Suppl 2:115-21.
Duc NB, Hien BT, Wagar N, Tram TH, Giang le T, Yang C, et al. Surveillance of transmitted HIV drug resistance using matched plasma and dried blood spot specimens from voluntary counseling and testing sites in Ho Chi Minh City, Vietnam, 2007-2008. Clin Infect Dis. 2012;54 Suppl 4:S343-7.
Tanuma J, Quang VM, Hachiya A, Joya A, Watanabe K, Gatanaga H, et al. Low prevalence of transmitted drug resistance of HIV-1 during 2008-2012 antiretroviral therapy scaling up in Southern Vietnam. J Acquir Immune Defic Syndr. 2014;66(4):358-64.
Pham QD, Do NT, Le YN, Nguyen TV, Nguyen DB, Huynh TK, et al. Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10. The Journal of antimicrobial chemotherapy. 2015;70(3):941-7.
WHO Western Pacifi Region. Road map for surveillance and monitoring of HIV drug resistance in the Western Pacific region 2014-2018. 58 pages p.
Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis. 2014;58(1):99-109.
Do D, Agneskog E, Nguyen T, Santacatterina M, Sönnerborg A, Larsson M. Monitoring the efficacy of antiretroviral therapy by a simple reverse transcriptase assay in HIV-infected adults in rural Vietnam. Future Virol. 2012;7(9 ):923–31.
WHO. Road Map for surveillance and monitoring of HIV drug resistance in the Western Pacific Region (2014-2018). Manila, Philippines: World Health Organization Regional Office for the Western Pacific; 2014. Available from: http://www.wpro.who.int/hiv/documents/docs/hivdr_roadmap/en/.
Rangarajan S, Donn JC, Giang le T, Bui DD, Hung Nguyen H, Tou PB, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad. 2016;2(2):94-101.
Downloads
Published
Issue
Section
License
© World Health Organization (WHO) 2018. Some rights reserved.
The articles in this publication are published by the World Health Organization and contain contributions by individual authors. The articles are available under the Creative Commons Attribution 3.0 IGO license (CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. In any use of these articles, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted.
Attribution
Please cite the articles as follows: [Author names]. [Article title]. Western Pac Surveill Response J. [Year]; [Volume] ([Issue]). [doi number] [pmid number]
For example, Hoy D, Saketa ST, Maraka RR, Sio A, Wanyeki I, Frison P, et al. Enhanced syndromic surveillance for mass gatherings in the Pacific: a case study of the 11th Festival of Pacific Arts in Solomon Islands, 2012. Western Pac Surveill Response J. 2016;7:3. doi:10.5365/wpsar.2016.7.1.004 pmid:27766181
License: Creative Commons BY 3.0 IGO
The World Health Organization does not necessarily own each component of the content contained within these articles and does not therefore warrant that the use of any third-party-owned individual component or part contained in the articles will not infringe on the rights of those third parties. The risk of claims resulting from such infringement rests solely with you. If you wish to re-use a component of the articles attributed to a third party, it is your responsibility to determine whether permission is needed for that re-use and to obtain permission from the copyright owner. Examples of components can include, but are not limited to, tables, figures or images.
Any mediation relating to disputes arising under this license shall be conducted in accordance with the WIPO Mediation Rules (www.wipo.int/amc/en/mediation/rules). Any inquiries should be addressed to publications@wpro.who.int.
License to publish
Western Pacific Surveillance and Response is an open access journal and requires each author of a contribution to grant the World Health Organization (the Publisher) a non-exclusive, worldwide, royalty-free license under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode) for the term of copyright and any extensions thereof. This includes to publish, re-publish, transmit, sell, distribute and otherwise use the article in the Journal, in whole or as a part. This is done by signing the WPSAR License to publish form.
Disclaimer
The designations employed and the presentation of the information on this website do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
Links to third-party websites
The World Health Organization does not warrant that the information contained on the website is complete and correct and shall not be liable whatsoever for any damages incurred as a result of its use.
